Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium

Mar 28, 2023 4:01pm EDT

Aptose Reports Results for the Fourth Quarter and Full Year 2022

Mar 23, 2023 4:44pm EDT

Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

Mar 10, 2023 6:44pm EST

Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023

Mar 09, 2023 4:05pm EST

Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference

Mar 02, 2023 7:30am EST

Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

Jan 30, 2023 7:00am EST

Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference

Dec 28, 2022 7:30am EST

Aptose Biosciences Establishes New At-The-Market Facility

Dec 12, 2022 6:15am EST

Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

Dec 11, 2022 9:00am EST

Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th

Dec 07, 2022 4:05pm EST